Tucatinib
- Generic Name
- Tucatinib
- Brand Names
- Tukysa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N8O2
- CAS Number
- 937263-43-9
- Unique Ingredient Identifier
- 234248D0HH
- Background
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other ch...
- Indication
本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。
- Associated Conditions
- Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
- Associated Therapies
- -
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Reva Basho
- Registration Number
- NCT04512261
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04499924
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- Conditions
- Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8HER2 Positive Breast CarcinomaInvasive Breast Carcinoma
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1031
- Registration Number
- NCT04457596
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Mount Carmel East Hospital, Columbus, Ohio, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04430738
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇯🇵National Cancer Center Hospital, Chuo-ku, Other, Japan
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Conditions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT04220203
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT03975647
- Locations
- 🇺🇸
Texas Oncology - Medical City Dallas, Dallas, Texas, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03914755
- Locations
- 🇺🇸
PAREXEL International, Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT03846583
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03826602
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Salt Lake City, Utah, United States
Effects of Tucatinib on Cardiac Repolarization in Healthy Participants
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT03777761
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.